Bausch & Lomb, the eye health company, and Galapagos have entered into a collaborative research agreement. Bausch & Lomb will have the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.
Helix BioMedix, a developer of bioactive peptides, has received US patent that covers more than eighty proprietary peptides for use in cosmetic and skin care applications and products, from the US Patent and Trademark Office.
Intellect Neurosciences has obtained a notice of allowance and completed the grant requirements to obtain a European patent relating to the company's Antisenilin antibodies and products being developed for the treatment of Alzheimer's disease.
Bavarian Nordic has reported that its innovative third-generation smallpox vaccine, Imvamune, has demonstrated a therapeutic effect of a smallpox vaccine, days after infection.
Biophan Technologies has said that Myotech, the company's majority-owned subsidiary, has entered into a memorandum of understanding with PPA Technologies to explore the potential for a strategic relationship regarding the development and commercialization of their respective technologies.
Haemacure has announced encouraging preclinical results of the company's lead product candidate, the human fibrin sealant Hemaseel HMN, in preventing the formation of post-surgical adhesions.
Taro Pharmaceutical Industries has appointed Ron Kolker as the new senior vice president and CFO of the company and its US subsidiary, Taro Pharmaceuticals USA.
HP and BT have signed a contract with Nycomed, an international pharmaceutical company, to outsource its infrastructure services over the next five years.
Biolase Technology has launched its new, minimally invasive Endolase RFT Root Canal Therapy System, which is said to enable endodontists and dentists to perform root canal procedures faster and more effectively than conventional treatment methods.
VioQuest Pharmaceuticals has raised an aggregate of approximately $3 million through the sale of units consisting of shares of its series A convertible preferred stock and warrants to purchase shares of its common stock, pursuant to a series of subscription
The HealthGrades's Patient Safety in American Hospitals study has revealed that patient safety incidents during 2004 to 2006 have resulted in the deaths of nearly 250,000 people apart from draining $8.8 billion from the US federal Medicare program, according to
Celgene International Sarl has announced that amrubicin hydrochloride has been designated as an orphan medicinal product by the European Commission for the treatment of small cell lung cancer following the favorable opinion of the European Medicines Agency's Committee for orphan
The European pharmaceutical industry has announced that it had never sought, direct-to-consumer advertising for prescription medicines to be permitted within the EU, reported PharmaTimes.
Teva Pharmaceutical Industries has reported encouraging results from a three-year study evaluating relapsing-remitting multiple sclerosis patients who failed first-line monotherapy and switched treatments.
Kraig Biocraft Laboratories has filed a provisional patent application describing a platform for antigen presentation and antibody test kits. The filing listed Malcolm Fraser, a member of Kraig's scientific advisory board, as the named inventor.
Antisoma has announced that its partner Novartis has started the pivotal Phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer.
Eli Lilly and Company has announced that the European health authorities have approved the use of Alimta for a histologically-based use in the first-line treatment of advanced non-small-cell lung cancer, the most common form of lung cancer.
Vermillion has received a patent for the discovery of novel forms of brain natriuretic peptide, which could potentially improve upon the current standard of care in diagnosing and treating cardiovascular disease, from the US Patent Office.
